ARCHIVES

Phase II Study Finds Dasatinib May Overcome ALL Resistance

This article is from The Cancer Letter archive.

Vol. 30 No. 5 | May 25, 2007

Download PDF Visit The Full Archive

Related Articles

Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III

June 28, 2013

Panel Urges New Research Consortium For Stomach, Esophageal Cancers

January 17, 2003

NCI Budget Picture: New Grants Down, No New Center Awards, Many Projects Left Unfunded

December 10, 1976

IOM Calls FDA Advisory System Sounds, Suggests Conflict Criteria Changes

March 5, 1993

SAIC Awarded $5 Billion Contract For NCI-Frederick.

October 3, 2008

NCI Programs: HMO Research Network wins $16 Million Grant for Prevention Studies

July 30, 1999